Recce Pharmaceuticals Limited (ASX:RCE) saw its shares move higher by 3.13% to AUD 0.50 on 1 May 2026, following the release of its quarterly Cash Flow Statement and operational update for Q3 FY2026. Over the past year, the stock has remained up by 70.69%, with investors reacting to a combination of non-dilutive funding inflows, ongoing clinical trial execution, and continued expansion of its anti-infective pipeline.

The latest update from the company focused on regulatory, clinical, and financial progress across multiple programs, including its Phase 3 trial in Indonesia and its ongoing collaboration with U.S. defence research institutions. The market response reflects a favourable interpretation of strengthened funding visibility and steady pipeline development.

Quarterly Update Anchored by Cash Inflow and Operational Progress

Recce Pharmaceuticals ended the quarter with a reported cash balance of AUD 1.7 million, supported by net operating cash inflows of AUD 1.6 million during Q3 FY2026. A key contributor to this inflow was government support, with AUD 5.3 million received under the Australian R&D Tax Incentive scheme for FY2025.

The company also highlighted that it expects an additional approximately AUD 3.5 million R&D rebate in the coming weeks, which would complete its FY2025 incentive cycle. Together, these inflows represent a material non-dilutive funding source supporting ongoing clinical and pre-clinical development activities.

Research and Development expenses remained the largest operating outflow at AUD 2.7 million, reflecting continued Investment into human Clinical Trials and supporting studies. Total payments to related parties, including executive and director fees, were recorded at AUD 0.7 million.

U.S. Army Collaboration Expands with Second CRADA Agreement

A key operational development during the quarter was Recce’s entry into a second Cooperative Research and Development Agreement (CRADA), this time with the U.S. Army Institute of Surgical Research (USAISR).

This collaboration is focused on evaluating RECCE 327 Gel (R327G) for burn wound infections using a validated preclinical burn wound model designed to replicate battlefield injury conditions. The study will assess the compound’s effectiveness against major pathogens such as Methicillin-Resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, both commonly associated with severe burn wound infections.

R327G is being developed as a synthetic, broad-spectrum anti-infective delivered through an amorphous gel formulation. The company noted its potential use in both military field applications and clinical wound care environments, with characteristics designed to support repeated use without reduced efficacy and with a reduced likelihood of bacterial resistance development.

This agreement follows an earlier CRADA with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), highlighting continued engagement with U.S. defence medical research programs. While no direct financial payments are associated with the agreement, it provides access to specialised research infrastructure and is considered strategically significant for the development pathway of R327G.

Brazil Patent Grant Strengthens Global Intellectual Property Position

During the quarter, Recce Pharmaceuticals also secured a Family 4 Patent grant in Brazil for its anti-infective technology, extending intellectual property protection until 2041. This marks the company’s seventh Family 4 Patent Jurisdiction, alongside Australia, Canada, China, Hong Kong, Israel, and Japan.

The Patent covers both RECCE 327 (R327) and RECCE 529 (R529), including methods of preparation and therapeutic applications across a range of infectious diseases. These include acute bacterial skin and skin structure infections (ABSSSI), diabetic foot infections, burn wound infections, urinary tract infections, gonorrhoea, influenza, and SARS-CoV-2, among others.

Administration routes under the Patent protection include oral, inhalation, injection, transdermal, aerosol, gel, topical foam, and ointment formulations.

Brazil represents a significant pharmaceutical market, particularly in antibiotics. The country’s antibiotics market was valued at approximately USD 774.5 million in 2024 and is projected to grow to USD 964.3 million by 2033. This positions the newly granted Patent as a meaningful addition to Recce’s commercial intellectual property footprint in a key regional market.

Clinical Development Progress Continues in Indonesia Phase 3 Trial

Recce continues to advance its registrational Phase 3 clinical trial in Indonesia for Diabetic Foot Infections (DFI). The trial is currently actively dosing patients across five clinical sites, with enrolment progressing towards a total target of up to 310 patients.

The study includes an interim data readout at 155 patients, with participants randomised to receive either R327G or placebo. The company has indicated that, subject to favourable results, it intends to pursue accelerated regulatory approval, with potential market entry targeted for 2026.

This program remains one of the key clinical value drivers for the company, particularly given the scale of the diabetic foot infection market and the unmet need in antibiotic-resistant infections.

Key Opinion Leader Engagement and Clinical Visibility

During the quarter, Recce also hosted a Key Opinion Leader (KOL) webinar featuring updates across its clinical and pre-clinical pipeline. The session included discussion on the Phase 3 diabetic foot infection study in Indonesia, as well as the U.S. Department of War burn wound program.

The webinar served as a platform to communicate progress across multiple programs and provided clinical and operational context for ongoing development initiatives. A recording of the session was made available by the company for investor access.

Capital Position Supported by Government Funding and Facilities

From a financial perspective, Recce’s funding position improved through a combination of government rebates and available financing facilities. The company reported total available funding of approximately AUD 22.6 million when combining cash, expected inflows, and unused Credit facilities.

At quarter end, total financing facilities stood at AUD 32.55 million, with AUD 11.64 million utilised. This leaves a substantial unused portion available for future operational requirements.

The company also maintains an At-the-Market (ATM) Equity Facility with Acuity Capital, although its usage remains limited. Management retains discretion over utilisation based on market conditions and Capital requirements.

What This Means for Investors?

The latest quarterly update from Recce Pharmaceuticals reflects continued clinical execution across key programs, alongside meaningful non-dilutive funding inflows from government R&D incentives. The second CRADA agreement with the U.S. Army adds further external validation of its anti-infective platform, while the Brazil Patent strengthens long-term intellectual property coverage in a key pharmaceutical market.

From a financial standpoint, the expected additional R&D rebate and existing funding facilities provide a degree of operational runway support. At the same time, the ongoing Phase 3 trial in Indonesia remains a key near-term catalyst, particularly as interim data milestones approach.

Overall, the update presents a combination of funding stability and pipeline progression, which appears to have supported investor sentiment in today’s Trading session.